Pioneering AMR Breakthroughs

MHCombiotic Inc. (MHC) is a Calgary-based biotech company tackling antimicrobial resistance (AMR) through groundbreaking research and innovation. Founded by Dr. Ali Pormohammad, Professor R J Turner, and CCrest Laboratory, MHC emerged from postdoctoral research at the University of Calgary and has collaborated with Harvard University, the University of Barcelona, and top research institutions across Canada and the U.S. Over three years, the team screened 18,000+ novel formulations, leading to the development of Combiotic™, a breakthrough product validated by FDA and Health Canada-approved labs.

Shaping the Future of AMR Treatment with Innovation

Our pioneering work has resulted in U.S. and international patents, multiple scientific publications, and prestigious awards, including Top 40 Under 40 and the 2024 Life Science Fellowship. Backed by CCrest Laboratory, a publicly traded pharmaceutical company, MHC is at the forefront of developing life-saving solutions to one of the world’s most pressing health challenges.

Innovation & Impact

Awards

Our Team

Collectively bring over 45 years of experience in combating antibiotic resistance and pioneering antimicrobial discovery

Dr. Ali Pormohammad

CEO, Co-Founder

Over 15 years of experience in antimicrobial innovation.

Prof. Raymond J. Turner

CSO, Co-Founder

25 years of experience in microbiology and AMR. Oversees and confirms methodologies used in preclinical and clinical trials at MHCombiotic

Alex Grenier

CBO

Over 15 years in the pharmaceutical industry. Manages regulatory strategy, market access, and commercialization. Successful exits in multiple ventures

Majid Behboudi

CCO

10+ years of pharmaceutical commercialization and marketing expertise. He excels in strategic planning, market analysis, and driving successful product launches

Himanshi Walia

Lead of Regulatory Affairs

Full-time regulatory agent at MHCombiotic.

Simran Jot Kaur

Lead of QMS

Full-time QMS specialist.

Advisory Board

Mark Ahrens-Townsend

Advisor

Former CEO of Biofilm
company
25+ years experience

Mohammad Zarei

Scientific Advisor

Pfizer-BioNTech
PhD, Research Fellow,
Harvard

Jeff Ryzner

Advisor
25+ years in
commercialization
experience

Next-Gen Antimicrobials: Transforming Infection Treatment

Innovative, science-backed solutions for wound care, respiratory infections, and animal health.

Cutting-edge antimicrobial solutions targeting biofilms, antibiotic resistance, and chronic infections in wound care, respiratory health, and animal health.